Industry Research Reports
Home > Reports > Service & Software > Global Canine Cancer Screening Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Canine Cancer Screening Market Outlook, In‑Depth Analysis & Forecast to 2031
Industry: Service & Software
Published Date: 2025-08-05
Pages: 143 Pages
Report ld: 4857153
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
The global Canine Cancer Screening market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Canine cancer screening is a process used to detect cancer in dogs at an early stage, often before symptoms become noticeable. Early detection can significantly improve the chances of successful treatment. Screening methods may include blood tests, imaging (such as X-rays or ultrasounds), and physical exams. Recently, there has also been progress in genetic testing and liquid biopsy techniques, which involve detecting cancer-related DNA or biomarkers in a dog's blood sample.
From a downstream perspective, Veterinary Clinics accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Canine Cancer Screening leading manufacturers including IDEXX, Mars Pedtcare, Zoetis, PetDx, Molecular Diagnostics (MDxHealth), Biomérieux SA, OncoK9, Antech Diagnostics, VolitionRx Limited, Oncotect, etc., dominate supply; the top five capture approximately % of global revenue, with IDEXX leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Canine Cancer Screening market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- IDEXX
- Mars Pedtcare
- Zoetis
- PetDx
- Molecular Diagnostics (MDxHealth)
- Biomérieux SA
- OncoK9
- Antech Diagnostics
- VolitionRx Limited
- Oncotect
- Heska Corporation
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Liquid Biopsy (Blood-Based Tests)
- Tissue Biopsy
- Genomic Testing
- Biomarker Tests
Segment by Application
- Veterinary Clinics
- Veterinary Hospitals
- Other
CHAPTER OUTLINE
Chapter 1: Defines the Canine Cancer Screening study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Canine Cancer Screening: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Canine Cancer Screening Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Liquid Biopsy (Blood-Based Tests)
1.2.3 Tissue Biopsy
1.2.4 Genomic Testing
1.2.5 Biomarker Tests
1.3 Market Segmentation by Application
1.3.1 Global Canine Cancer Screening Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Veterinary Clinics
1.3.3 Veterinary Hospitals
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Canine Cancer Screening Revenue Estimates and Forecasts 2020-2031
2.2 Global Canine Cancer Screening Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Canine Cancer Screening Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Canine Cancer Screening Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Liquid Biopsy (Blood-Based Tests) Market Size by Players
3.3.2 Tissue Biopsy Market Size by Players
3.3.3 Genomic Testing Market Size by Players
3.3.4 Biomarker Tests Market Size by Players
3.4 Global Canine Cancer Screening Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Canine Cancer Screening Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Canine Cancer Screening Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Canine Cancer Screening Market Size by Type (2020-2031)
6.4 North America Canine Cancer Screening Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Canine Cancer Screening Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Canine Cancer Screening Market Size by Type (2020-2031)
7.4 Europe Canine Cancer Screening Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Canine Cancer Screening Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Canine Cancer Screening Market Size by Type (2020-2031)
8.4 Asia-Pacific Canine Cancer Screening Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Canine Cancer Screening Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Canine Cancer Screening Market Size by Type (2020-2031)
9.4 Central and South America Canine Cancer Screening Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Canine Cancer Screening Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Canine Cancer Screening Market Size by Type (2020-2031)
10.4 Middle East and Africa Canine Cancer Screening Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Canine Cancer Screening Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 IDEXX
11.1.1 IDEXX Corporation Information
11.1.2 IDEXX Business Overview
11.1.3 IDEXX Canine Cancer Screening Product Features and Attributes
11.1.4 IDEXX Canine Cancer Screening Revenue and Gross Margin (2020-2025)
11.1.5 IDEXX Canine Cancer Screening Revenue by Product in 2024
11.1.6 IDEXX Canine Cancer Screening Revenue by Application in 2024
11.1.7 IDEXX Canine Cancer Screening Revenue by Geographic Area in 2024
11.1.8 IDEXX Canine Cancer Screening SWOT Analysis
11.1.9 IDEXX Recent Developments
11.2 Mars Pedtcare
11.2.1 Mars Pedtcare Corporation Information
11.2.2 Mars Pedtcare Business Overview
11.2.3 Mars Pedtcare Canine Cancer Screening Product Features and Attributes
11.2.4 Mars Pedtcare Canine Cancer Screening Revenue and Gross Margin (2020-2025)
11.2.5 Mars Pedtcare Canine Cancer Screening Revenue by Product in 2024
11.2.6 Mars Pedtcare Canine Cancer Screening Revenue by Application in 2024
11.2.7 Mars Pedtcare Canine Cancer Screening Revenue by Geographic Area in 2024
11.2.8 Mars Pedtcare Canine Cancer Screening SWOT Analysis
11.2.9 Mars Pedtcare Recent Developments
11.3 Zoetis
11.3.1 Zoetis Corporation Information
11.3.2 Zoetis Business Overview
11.3.3 Zoetis Canine Cancer Screening Product Features and Attributes
11.3.4 Zoetis Canine Cancer Screening Revenue and Gross Margin (2020-2025)
11.3.5 Zoetis Canine Cancer Screening Revenue by Product in 2024
11.3.6 Zoetis Canine Cancer Screening Revenue by Application in 2024
11.3.7 Zoetis Canine Cancer Screening Revenue by Geographic Area in 2024
11.3.8 Zoetis Canine Cancer Screening SWOT Analysis
11.3.9 Zoetis Recent Developments
11.4 PetDx
11.4.1 PetDx Corporation Information
11.4.2 PetDx Business Overview
11.4.3 PetDx Canine Cancer Screening Product Features and Attributes
11.4.4 PetDx Canine Cancer Screening Revenue and Gross Margin (2020-2025)
11.4.5 PetDx Canine Cancer Screening Revenue by Product in 2024
11.4.6 PetDx Canine Cancer Screening Revenue by Application in 2024
11.4.7 PetDx Canine Cancer Screening Revenue by Geographic Area in 2024
11.4.8 PetDx Canine Cancer Screening SWOT Analysis
11.4.9 PetDx Recent Developments
11.5 Molecular Diagnostics (MDxHealth)
11.5.1 Molecular Diagnostics (MDxHealth) Corporation Information
11.5.2 Molecular Diagnostics (MDxHealth) Business Overview
11.5.3 Molecular Diagnostics (MDxHealth) Canine Cancer Screening Product Features and Attributes
11.5.4 Molecular Diagnostics (MDxHealth) Canine Cancer Screening Revenue and Gross Margin (2020-2025)
11.5.5 Molecular Diagnostics (MDxHealth) Canine Cancer Screening Revenue by Product in 2024
11.5.6 Molecular Diagnostics (MDxHealth) Canine Cancer Screening Revenue by Application in 2024
11.5.7 Molecular Diagnostics (MDxHealth) Canine Cancer Screening Revenue by Geographic Area in 2024
11.5.8 Molecular Diagnostics (MDxHealth) Canine Cancer Screening SWOT Analysis
11.5.9 Molecular Diagnostics (MDxHealth) Recent Developments
11.6 Biomérieux SA
11.6.1 Biomérieux SA Corporation Information
11.6.2 Biomérieux SA Business Overview
11.6.3 Biomérieux SA Canine Cancer Screening Product Features and Attributes
11.6.4 Biomérieux SA Canine Cancer Screening Revenue and Gross Margin (2020-2025)
11.6.5 Biomérieux SA Recent Developments
11.7 OncoK9
11.7.1 OncoK9 Corporation Information
11.7.2 OncoK9 Business Overview
11.7.3 OncoK9 Canine Cancer Screening Product Features and Attributes
11.7.4 OncoK9 Canine Cancer Screening Revenue and Gross Margin (2020-2025)
11.7.5 OncoK9 Recent Developments
11.8 Antech Diagnostics
11.8.1 Antech Diagnostics Corporation Information
11.8.2 Antech Diagnostics Business Overview
11.8.3 Antech Diagnostics Canine Cancer Screening Product Features and Attributes
11.8.4 Antech Diagnostics Canine Cancer Screening Revenue and Gross Margin (2020-2025)
11.8.5 Antech Diagnostics Recent Developments
11.9 VolitionRx Limited
11.9.1 VolitionRx Limited Corporation Information
11.9.2 VolitionRx Limited Business Overview
11.9.3 VolitionRx Limited Canine Cancer Screening Product Features and Attributes
11.9.4 VolitionRx Limited Canine Cancer Screening Revenue and Gross Margin (2020-2025)
11.9.5 VolitionRx Limited Recent Developments
11.10 Oncotect
11.10.1 Oncotect Corporation Information
11.10.2 Oncotect Business Overview
11.10.3 Oncotect Canine Cancer Screening Product Features and Attributes
11.10.4 Oncotect Canine Cancer Screening Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Heska Corporation
11.11.1 Heska Corporation Corporation Information
11.11.2 Heska Corporation Business Overview
11.11.3 Heska Corporation Canine Cancer Screening Product Features and Attributes
11.11.4 Heska Corporation Canine Cancer Screening Revenue and Gross Margin (2020-2025)
11.11.5 Heska Corporation Recent Developments
12 Canine Cancer ScreeningIndustry Chain Analysis
12.1 Canine Cancer Screening Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Canine Cancer Screening Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Canine Cancer Screening Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Canine Cancer Screening Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Canine Cancer Screening Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Canine Cancer Screening Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Canine Cancer Screening Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Canine Cancer Screening Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Canine Cancer Screening Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Canine Cancer Screening Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Canine Cancer Screening by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Canine Cancer Screening as of 2024)
Table 11. Global Canine Cancer Screening Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Canine Cancer Screening Companies Headquarters
Table 13. Global Canine Cancer Screening Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Canine Cancer Screening Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Canine Cancer Screening Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Canine Cancer Screening Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Canine Cancer Screening Revenue by Application (2026-2031) & (US$ Million)
Table 21. Canine Cancer Screening High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Canine Cancer Screening Growth Accelerators and Market Barriers
Table 25. North America Canine Cancer Screening Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Canine Cancer Screening Growth Accelerators and Market Barriers
Table 27. Europe Canine Cancer Screening Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Canine Cancer Screening Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Canine Cancer Screening Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Canine Cancer Screening Investment Opportunities and Key Challenges
Table 31. Central and South America Canine Cancer Screening Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Canine Cancer Screening Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Canine Cancer Screening Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. IDEXX Corporation Information
Table 35. IDEXX Description and Major Businesses
Table 36. IDEXX Product Features and Attributes
Table 37. IDEXX Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. IDEXX Revenue Proportion by Product in 2024
Table 39. IDEXX Revenue Proportion by Application in 2024
Table 40. IDEXX Revenue Proportion by Geographic Area in 2024
Table 41. IDEXX Canine Cancer Screening SWOT Analysis
Table 42. IDEXX Recent Developments
Table 43. Mars Pedtcare Corporation Information
Table 44. Mars Pedtcare Description and Major Businesses
Table 45. Mars Pedtcare Product Features and Attributes
Table 46. Mars Pedtcare Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Mars Pedtcare Revenue Proportion by Product in 2024
Table 48. Mars Pedtcare Revenue Proportion by Application in 2024
Table 49. Mars Pedtcare Revenue Proportion by Geographic Area in 2024
Table 50. Mars Pedtcare Canine Cancer Screening SWOT Analysis
Table 51. Mars Pedtcare Recent Developments
Table 52. Zoetis Corporation Information
Table 53. Zoetis Description and Major Businesses
Table 54. Zoetis Product Features and Attributes
Table 55. Zoetis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Zoetis Revenue Proportion by Product in 2024
Table 57. Zoetis Revenue Proportion by Application in 2024
Table 58. Zoetis Revenue Proportion by Geographic Area in 2024
Table 59. Zoetis Canine Cancer Screening SWOT Analysis
Table 60. Zoetis Recent Developments
Table 61. PetDx Corporation Information
Table 62. PetDx Description and Major Businesses
Table 63. PetDx Product Features and Attributes
Table 64. PetDx Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. PetDx Revenue Proportion by Product in 2024
Table 66. PetDx Revenue Proportion by Application in 2024
Table 67. PetDx Revenue Proportion by Geographic Area in 2024
Table 68. PetDx Canine Cancer Screening SWOT Analysis
Table 69. PetDx Recent Developments
Table 70. Molecular Diagnostics (MDxHealth) Corporation Information
Table 71. Molecular Diagnostics (MDxHealth) Description and Major Businesses
Table 72. Molecular Diagnostics (MDxHealth) Product Features and Attributes
Table 73. Molecular Diagnostics (MDxHealth) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Molecular Diagnostics (MDxHealth) Revenue Proportion by Product in 2024
Table 75. Molecular Diagnostics (MDxHealth) Revenue Proportion by Application in 2024
Table 76. Molecular Diagnostics (MDxHealth) Revenue Proportion by Geographic Area in 2024
Table 77. Molecular Diagnostics (MDxHealth) Canine Cancer Screening SWOT Analysis
Table 78. Molecular Diagnostics (MDxHealth) Recent Developments
Table 79. Biomérieux SA Corporation Information
Table 80. Biomérieux SA Description and Major Businesses
Table 81. Biomérieux SA Product Features and Attributes
Table 82. Biomérieux SA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Biomérieux SA Recent Developments
Table 84. OncoK9 Corporation Information
Table 85. OncoK9 Description and Major Businesses
Table 86. OncoK9 Product Features and Attributes
Table 87. OncoK9 Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. OncoK9 Recent Developments
Table 89. Antech Diagnostics Corporation Information
Table 90. Antech Diagnostics Description and Major Businesses
Table 91. Antech Diagnostics Product Features and Attributes
Table 92. Antech Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Antech Diagnostics Recent Developments
Table 94. VolitionRx Limited Corporation Information
Table 95. VolitionRx Limited Description and Major Businesses
Table 96. VolitionRx Limited Product Features and Attributes
Table 97. VolitionRx Limited Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. VolitionRx Limited Recent Developments
Table 99. Oncotect Corporation Information
Table 100. Oncotect Description and Major Businesses
Table 101. Oncotect Product Features and Attributes
Table 102. Oncotect Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Oncotect Recent Developments
Table 104. Heska Corporation Corporation Information
Table 105. Heska Corporation Description and Major Businesses
Table 106. Heska Corporation Product Features and Attributes
Table 107. Heska Corporation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Heska Corporation Recent Developments
Table 109. Raw Materials Key Suppliers
Table 110. Distributors List
Table 111. Market Trends and Market Evolution
Table 112. Market Drivers and Opportunities
Table 113. Market Challenges, Risks, and Restraints
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Canine Cancer Screening Product Picture
Figure 2. Global Canine Cancer Screening Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Liquid Biopsy (Blood-Based Tests) Product Picture
Figure 4. Tissue Biopsy Product Picture
Figure 5. Genomic Testing Product Picture
Figure 6. Biomarker Tests Product Picture
Figure 7. Global Canine Cancer Screening Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Veterinary Clinics
Figure 9. Veterinary Hospitals
Figure 10. Other
Figure 11. Canine Cancer Screening Report Years Considered
Figure 12. Global Canine Cancer Screening Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 14. Global Canine Cancer Screening Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Canine Cancer Screening Revenue Market Share by Region (2020-2031)
Figure 16. Global Canine Cancer Screening Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Liquid Biopsy (Blood-Based Tests) Revenue Market Share by Player in 2024
Figure 19. Tissue Biopsy Revenue Market Share by Player in 2024
Figure 20. Genomic Testing Revenue Market Share by Player in 2024
Figure 21. Biomarker Tests Revenue Market Share by Player in 2024
Figure 22. Global Canine Cancer Screening Revenue Market Share by Type (2020-2031)
Figure 23. Global Canine Cancer Screening Revenue Market Share by Application (2020-2031)
Figure 24. North America Canine Cancer Screening Revenue YoY (2020-2031) & (US$ Million)
Figure 25. North America Top 5 Players Canine Cancer Screening Revenue (US$ Million) in 2024
Figure 26. North America Canine Cancer Screening Revenue (US$ Million) by Type (2020 - 2031)
Figure 27. North America Canine Cancer Screening Revenue (US$ Million) by Application (2020-2031)
Figure 28. US Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 29. Canada Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 30. Mexico Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 31. Europe Canine Cancer Screening Revenue YoY (2020-2031) & (US$ Million)
Figure 32. Europe Top 5 Players Canine Cancer Screening Revenue (US$ Million) in 2024
Figure 33. Europe Canine Cancer Screening Revenue (US$ Million) by Type (2020-2031)
Figure 34. Europe Canine Cancer Screening Revenue (US$ Million) by Application (2020-2031)
Figure 35. Germany Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 36. France Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 37. U.K. Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 38. Italy Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 39. Russia Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Canine Cancer Screening Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Top 8 Players Canine Cancer Screening Revenue (US$ Million) in 2024
Figure 42. Asia-Pacific Canine Cancer Screening Revenue (US$ Million) by Type (2020-2031)
Figure 43. Asia-Pacific Canine Cancer Screening Revenue (US$ Million) by Application (2020-2031)
Figure 44. Indonesia Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 45. Japan Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 46. South Korea Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 47. Australia Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 48. India Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 49. Indonesia Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 50. Vietnam Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 51. Malaysia Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 52. Philippines Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 53. Singapore Canine Cancer Screening Revenue (2020-2031) & (US$ Million)
Figure 54. Central and South America Canine Cancer Screening Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Central and South America Top 5 Players Canine Cancer Screening Revenue (US$ Million) in 2024
Figure 56. Central and South America Canine Cancer Screening Revenue (US$ Million) by Type (2020-2031)
Figure 57. Central and South America Canine Cancer Screening Revenue (US$ Million) by Application (2020-2031)
Figure 58. Brazil Canine Cancer Screening Revenue (2020-2025) & (US$ Million)
Figure 59. Argentina Canine Cancer Screening Revenue (2020-2025) & (US$ Million)
Figure 60. Middle East and Africa Canine Cancer Screening Revenue YoY (2020-2031) & (US$ Million)
Figure 61. Middle East and Africa Top 5 Players Canine Cancer Screening Revenue (US$ Million) in 2024
Figure 62. South America Canine Cancer Screening Revenue (US$ Million) by Type (2020-2031)
Figure 63. Middle East and Africa Canine Cancer Screening Revenue (US$ Million) by Application (2020-2031)
Figure 64. GCC Countries Canine Cancer Screening Revenue (2020-2025) & (US$ Million)
Figure 65. Israel Canine Cancer Screening Revenue (2020-2025) & (US$ Million)
Figure 66. Egypt Canine Cancer Screening Revenue (2020-2025) & (US$ Million)
Figure 67. South Africa Canine Cancer Screening Revenue (2020-2025) & (US$ Million)
Figure 68. Canine Cancer Screening Industry Chain Mapping
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which companies rank high in the global Canine Cancer Screening market?
The top companies in the global Canine Cancer Screening market are IDEXX、Mars Pedtcare、Zoetis.
Related Reports
Global Canine Cancer Screening Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Canine Cancer Screening market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-26
Pages: 143
USD 4900.00
(Single User License)
Global Canine Cancer Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Canine Cancer Screening market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published Date: 2026-03-26
Pages: 97
USD 4250.00
(Single User License)
Canine Cancer Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Canine Cancer Screening was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-01-09
Pages: 113
USD 3950.00
(Single User License)
Global Canine Cancer Screening Market Research Report 2026
The global Canine Cancer Screening market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-01-09
Pages: 115
USD 2900.00
(Single User License)
Global Canine Cancer Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Canine Cancer Screening market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-09-06
Pages: 95
USD 4250.00
(Single User License)
Canine Cancer Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Canine Cancer Screening was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-03-12
Pages: 116
USD 3950.00
(Single User License)
Global Canine Cancer Screening Market Research Report 2025
The global market for Canine Cancer Screening was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-03-12
Pages: 82
USD 2900.00
(Single User License)
Global Canine Cancer Screening Market Research Report 2024
Canine cancer screening is a process used to detect cancer in dogs at an early stage, often before symptoms become noticeable. Early detection can significantly improve the chances of successful treatment. Screening methods may include blood tests, imaging (such as X-rays or ultrasounds), and physical exams. Recently, there has also been progress in genetic testing and liquid biopsy techniques, which involve detecting cancer-related DNA or biomarkers in a dog's blood sample.
Published Date: 2024-09-24
Pages: 83
USD 2900.00
(Single User License)
Global and United States Canine Cancer Screening Market Report & Forecast 2024-2030
Canine cancer screening is a process used to detect cancer in dogs at an early stage, often before symptoms become noticeable. Early detection can significantly improve the chances of successful treatment. Screening methods may include blood tests, imaging (such as X-rays or ultrasounds), and physical exams. Recently, there has also been progress in genetic testing and liquid biopsy techniques, which involve detecting cancer-related DNA or biomarkers in a dog's blood sample.
Published Date: 2024-09-24
Pages: 106
USD 4350.00
(Single User License)
Global Canine Cancer Screening Market Insights, Forecast to 2030
Canine cancer screening is a process used to detect cancer in dogs at an early stage, often before symptoms become noticeable. Early detection can significantly improve the chances of successful treatment. Screening methods may include blood tests, imaging (such as X-rays or ultrasounds), and physical exams. Recently, there has also been progress in genetic testing and liquid biopsy techniques, which involve detecting cancer-related DNA or biomarkers in a dog's blood sample.
Published Date: 2024-09-24
Pages: 134
USD 4900.00
(Single User License)
Global Canine Cancer Screening Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Canine Cancer Screening market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-26
Pages: 143
USD 4900.00 (Single User License)Global Canine Cancer Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Canine Cancer Screening market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published: 2026-03-26
Pages: 97
USD 4250.00 (Single User License)Canine Cancer Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Canine Cancer Screening was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-01-09
Pages: 113
USD 3950.00 (Single User License)Global Canine Cancer Screening Market Research Report 2026
The global Canine Cancer Screening market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-01-09
Pages: 115
USD 2900.00 (Single User License)Global Canine Cancer Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Canine Cancer Screening market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-09-06
Pages: 95
USD 4250.00 (Single User License)Canine Cancer Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Canine Cancer Screening was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-03-12
Pages: 116
USD 3950.00 (Single User License)Global Canine Cancer Screening Market Research Report 2025
The global market for Canine Cancer Screening was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-03-12
Pages: 82
USD 2900.00 (Single User License)Global Canine Cancer Screening Market Research Report 2024
Canine cancer screening is a process used to detect cancer in dogs at an early stage, often before symptoms become noticeable. Early detection can significantly improve the chances of successful treatment. Screening methods may include blood tests, imaging (such as X-rays or ultrasounds), and physical exams. Recently, there has also been progress in genetic testing and liquid biopsy techniques, which involve detecting cancer-related DNA or biomarkers in a dog's blood sample.
Published: 2024-09-24
Pages: 83
USD 2900.00 (Single User License)Global and United States Canine Cancer Screening Market Report & Forecast 2024-2030
Canine cancer screening is a process used to detect cancer in dogs at an early stage, often before symptoms become noticeable. Early detection can significantly improve the chances of successful treatment. Screening methods may include blood tests, imaging (such as X-rays or ultrasounds), and physical exams. Recently, there has also been progress in genetic testing and liquid biopsy techniques, which involve detecting cancer-related DNA or biomarkers in a dog's blood sample.
Published: 2024-09-24
Pages: 106
USD 4350.00 (Single User License)Global Canine Cancer Screening Market Insights, Forecast to 2030
Canine cancer screening is a process used to detect cancer in dogs at an early stage, often before symptoms become noticeable. Early detection can significantly improve the chances of successful treatment. Screening methods may include blood tests, imaging (such as X-rays or ultrasounds), and physical exams. Recently, there has also been progress in genetic testing and liquid biopsy techniques, which involve detecting cancer-related DNA or biomarkers in a dog's blood sample.
Published: 2024-09-24
Pages: 134
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now